Dader method to provide pharmacotherapy follow up

El seguimiento farmacoterapéutico es una práctica profesional en la que el farmacéutico se responsabiliza de las necesidades del paciente sobre sus medicamentos, mediante la detección, prevención y resolución de problemas relacionados con los medicamentos. El Método Dáder para el seguimiento farmacoterapéutico ha sido diseñado por el Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada. Se basa en la obtención de la historia farmacoterapéutica del paciente, evaluación del estado de situación, identificación de las sospechas de problemas relacionados con los medicamentos, intervención farmacéutica y evaluación de los resultados obtenidos. Se describen los distintos procesos del método y la documentación utilizada. El Método Dáder se utiliza desde el año 2000, en diferentes países, por cientos de farmacéuticos que lo están aplicando a miles de pacientes.Pharmacotherapy follow up is a professional practice in which the pharmacist is responsible for the medicine-related needs expressed by the patients, by detecting, preventing and solving drug related problems. The Dáder Method for pharmacotherapy follow up has been developed by the Pharmaceutical Care Research Group of the University of Granada, in Spain. It is based on the use of the patient’ pharmacotherapy record, the assessment of his assessment form, the identification of drug related problems, the consequent pharmacist intervention and the evaluation of the achieved outcomes. In this paper, the different carried out processes and the documentation system used in this method, are described. The Dáder Method has been used in numerous countries, by hundreds of pharmacists, and applied to thousands of patients

Método Dáder para el seguimiento farmacoterapéutico

Pharmacotherapy follow up is a professional practice in which the pharmacist is responsible for themedicine-related needs expressed by the patients, by detecting, preventing and solving drug relatedproblems. The Dáder Method for pharmacotherapy follow up has been developed by the PharmaceuticalCare Research Group of the University of Granada, in Spain. It is based on the use of the patient’pharmacotherapy record, the assessment of his assessment form, the identification of drug relatedproblems, the consequent pharmacist intervention and the evaluation of the achieved outcomes. In thispaper, the different carried out processes and the documentation system used in this method, aredescribed. The Dáder Method has been used in numerous countries, by hundreds of pharmacists, andapplied to thousands of patients.El seguimiento farmacoterapéutico es una práctica profesional en la que el farmacéutico se responsabilizade las necesidades del paciente sobre sus medicamentos, mediante la detección, prevención y resoluciónde problemas relacionados con los medicamentos. El Método Dáder para el seguimiento farmacoterapéuticoha sido diseñado por el Grupo de Investigación en Atención Farmacéutica de la Universidad de Granada.Se basa en la obtención de la historia farmacoterapéutica del paciente, evaluación del estado de situación,identificación de las sospechas de problemas relacionados con los medicamentos, intervención farmacéuticay evaluación de los resultados obtenidos. Se describen los distintos procesos del método y ladocumentación utilizada. El Método Dáder se utiliza desde el año 2000, en diferentes países, por cientosde farmacéuticos que lo están aplicando a miles de pacientes

Second consensus of Granada on drug therapy problems

Ante la prevalencia de los problemas derivados del uso de medicamentos se estableció el concepto de Problema Relacionado con Medicamentos. En 1998 se realizó un primer Consenso de Granada sobre PRM en el que se definió este término y se estableció una clasificación de 6 categorías. Tras la experiencia de su uso se han podido detectar algunos problemas de comprensión que recomendaron la actualización en un Segundo Consenso de Granada sobre Problemas relacionados con los medicamentos. Se definen como resultados clínicos negativos de la farmacoterapia y se enuncian las seis categorías de PRM en función de los problemas de salud que sufre el paciente.Due to the prevalence of problems resulting from the use of medicines, the concept of Drug Therapy Problem was established. In 1998 a first Consensus of Granada on Drug-related Problems was hold in which this term was defined and a 6 categories classification was established. After the experience of its use, some understanding problems have been detected which recommended the up-date in a Second Consensus of Granada on Drug Therapy Problems. They were defined as negative clinical outcomes of drug therapy and the DTP six categories were described in function of the health problems that patient suffers

Third consensus of Granada on drug related problems (DRP) and negative outcomes associated with medication (NOM)

Como consecuencia de la prevalencia de los problemas derivados del uso de medicamentos, en 1990 se estableció el concepto de Problema Relacionado con Medicamentos (PRM). En España en 1998 se realizó un primer Consenso de Granada sobre PRM, en el que se defi nió este término y se estableció una clasifi cación en 6 categorías. Tras la experiencia con esta defi nición y con esta clasifi cación, se actualizó en el Segundo Consenso de Granada sobre Problemas Relacionados con Medicamentos, publicado en 2002. En este tercer Consenso de Granada sobre Problemas Relacionados con Medicamentos (PRM) y Resultados Negativos asociados a la Medicación (RNM), se asume la entidad de los PRM como elementos de proceso y como causas de RNM. Se defi nen a los PRM y RNM, se propone un listado de PRM y una clasifi cación de RNM. Finalmente se adapta la defi nición de Seguimiento Farmacoterapéutico del Consenso sobre Atención Farmacéutica del Ministerio de Sanidad y Consumo de España, publicado en 2001, utilizando los nuevos conceptos de PRM y RNM.As a consequence of the widespread prevalence of problems associated with the use of medicines, the concept of Drug Related Problems (DRP) was established in 1990 in Spain. Through the fi rst Consensus of Granada in 1998, a defi nition of this term was reached, in which the varying related problems were classifi ed into 6 categories. With the experience gained from this defi nition and classifi cation, a second consensus was subsequently published in 2002, which in turn has now lead to the third Consensus of Granada on Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM), recognising the signifi cance of DRPs as elements of process and as the cause of (NOM). In this third work, DRPs and NOMs are defi ned, and a list of DRPs and a classifi cation of NOMs has been compiled. Finally, the defi nition of Pharmacotherapy Monitoring from the Consensus on Pharmaceutical Care of the Ministry of Health and Consumption of Spain published in 2001 was adapted, in accordance with new concepts of MRP and NOM

Impact of Pharmacists’ Participation in a Pharmacotherapy Follow-Up Program

Objective. To evaluate the impact of a continuing pharmacy education (CPE) course on Spanish community pharmacists’ participation in a pharmacotherapy follow-up program

Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial

<p>Abstract</p> <p>Background</p> <p>Pharmaceutical care is the direct interaction between pharmacist and patient, in order to improve therapeutic compliance, promote adequate pharmacotherapeutic follow-up, and improve quality of life. Pharmaceutical care may be effective in reducing complications and in improving the quality of life of patients with chronic diseases, like Chagas heart disease, while bringing a positive impact on health system costs. The morbidity and mortality indexes for patients with Chagas heart disease are high, especially if this heart disease is complicated by heart failure. In this setting, we hypothesize that pharmaceutical care might be an important tool for the clinical management of these patients by improving their quality of life, as a better compliance to their treatment and the avoidance and prompt correction of drug-related problems will minimize their symptoms, improve their functional class, and decrease the number of hospital admissions. Therefore, the aim of this trial is to evaluate the contribution of pharmaceutical care to clinical treatment of patients with Chagas heart disease complicated by heart failure.</p> <p>Methods/design</p> <p>A prospective, single-center randomized clinical trial will be conducted in patients with Chagas heart disease complicated by heart failure. A total of 88 patients will be randomly assigned into two parallel groups: an intervention group will receive standard care and pharmaceutical care, and a control group will receive only standard care. Both groups will be subjected to a follow-up period of 12 months. The primary outcome of this trial is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure Questionnaire. Secondary outcomes include drug-related problems, exercise tolerance as measured by the standard six-minute-walk test, and compliance.</p> <p>Discussion</p> <p>Patients with Chagas heart disease complicated by heart failure under pharmaceutical care are expected to improve their quality of life, present with a lower incidence of drug-related problems, improve their functional capacity, and improve in their compliance to treatment.</p> <p>Trial registration</p> <p>ClinicalTrials.gov Identifier: NCT01566617</p